Perspective Therapeutics (CATX) Projected to Post Earnings on Monday

Perspective Therapeutics (NYSEAMERICAN:CATX) is anticipated to announce its Q3 2026 resultson Monday, November 9th. Analysts expect the company to post earnings of ($0.24) per share and revenue of $0.06 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. The company had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. On average, analysts expect Perspective Therapeutics to post ($0.98) EPS for the current fiscal year and ($1.09) EPS for the next fiscal year.

Perspective Therapeutics Price Performance

CATX stock opened at $1.15 on Monday. The firm has a fifty day moving average price of $2.57 and a 200 day moving average price of $3.53. Perspective Therapeutics has a fifty-two week low of $1.06 and a fifty-two week high of $6.16.

Wall Street Analyst Weigh In

CATX has been the subject of several analyst reports. Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and lowered their target price for the stock from $14.00 to $4.00 in a report on Monday, October 26th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday. William Blair began coverage on Perspective Therapeutics in a research note on Friday, September 18th. They set an “outperform” rating for the company. BTIG Research restated a “buy” rating on shares of Perspective Therapeutics in a report on Monday, October 26th. Finally, Bank of America cut their price objective on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.50.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a biotechnology company developing precision-targeted radiopharmaceutical treatments for cancer. The company’s platform is designed to deliver alpha-particle radiation directly to tumor cells by pairing radioactive isotopes with molecules that bind to specific cancer targets, with the goal of limiting damage to surrounding healthy tissue.

The company’s lead programs include VMT-?-NET, an investigational therapy directed at somatostatin receptor 2, a target commonly expressed by neuroendocrine tumors.